AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7721525 — intervention group
Group type: COMPARATOR
Intervention: Space-Heated Room (SHR)
Number of subjects: 62
Study 2529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin 1200 micrograms/day for 6 months
Number of subjects: 62
Study 2529770 — intervention group
Group type: COMPARATOR
Intervention: Danazol 600 micrograms/day for 6 months
Number of subjects: 62
Study 1097864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Number of subjects: 0
Study 1097864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30833645 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloplast Titan
Number of subjects: 100
Study 30833645 — intervention group
Group type: COMPARATOR
Intervention: Coloplast Titan Touch
Number of subjects: 100
Study 30833645 — intervention group
Group type: COMPARATOR
Intervention: AMS 700
Number of subjects: 100
Study 31265756 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral sedation
Number of subjects: 904
Study 31265756 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 65 years and older
Number of subjects: 904
Study 31265756 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one type of parenteral sedation administered within 60 minutes
Number of subjects: 904
Study 31265756 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 904
Study 28425449 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 169
Study 28425449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 169
Study 28425449 — intervention group
Group type: COMPARATOR
Intervention: Placebo-pill treatment
Number of subjects: 169
Study 28425449 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 169
Study 25458637 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF plus empirical antibiotics (Group I)
Number of subjects: 56
Study 25458637 — intervention group
Group type: COMPARATOR
Intervention: Empirical antibiotics alone (Group II)
Number of subjects: 56
Study 23057583 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with high arousal
Number of subjects: 0
Study 23057583 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with low arousal
Number of subjects: 0
Study 23057583 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with high arousal
Number of subjects: 0
Study 23057583 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with low arousal
Number of subjects: 0
Study 23057583 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood
Number of subjects: 0
Study 23057583 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 21467561 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Preanesthetic Set‐Up
Number of subjects: 200
Study 21467561 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia technique
Number of subjects: 200
Study 21467561 — intervention group
Group type: COMPARATOR
Intervention: Higher case loads (≥5 cases scheduled)
Number of subjects: 200
Study 21467561 — intervention group
Group type: COMPARATOR
Intervention: Set-up completed by attending anesthesiologists
Number of subjects: 200
Study 17391746 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological neighbor (mouse)
Number of subjects: 0
Study 17391746 — intervention group
Group type: COMPARATOR
Intervention: Unrelated word (lamp)
Number of subjects: 0
Study 17117001 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (3 times a week for 8 weeks)
Number of subjects: 26
Study 17117001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 15146224 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer survivors
Number of subjects: 30
Study 15146224 — intervention group
Group type: COMPARATOR
Intervention: Healthy women
Number of subjects: 30
Study 15146224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 11587368 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Number of subjects: 1200
Study 11587368 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 1200
Study 11587368 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1200
Study 11587368 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC trial (specific to autograft)
Number of subjects: 1200
Study 9205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 5 mg tid
Number of subjects: 13
Study 9205016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8204996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168
Study 8204996 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168
Study 8204996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study 3330528 — intervention group
Group type: EXPERIMENTAL
Intervention: ST 567 3 X 30 mg
Number of subjects: 48
Study 3330528 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 3 X 40 mg
Number of subjects: 48
Study 30924578 — intervention group
Group type: EXPERIMENTAL
Intervention: fast-acting insulin aspart (faster aspart)
Number of subjects: 236
Study 30924578 — intervention group
Group type: COMPARATOR
Intervention: basal-only insulin
Number of subjects: 236
Study 28620916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 135
Study 28620916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 135
Study 28620916 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 135
Study 28620916 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Ketamine 0.2 mg/kg, Ketamine 0.4 mg/kg, Saline)
Number of subjects: 135
Study 26571892 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Tianshu (ST 25), Fujie (SP 14) with dense‐disperse wave (2Hz/15 Hz, 0.1 to 1.0 mA) and Shangjuxu (ST 37) needled, treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Number of subjects: 70
Study 26571892 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (sham‐EA) at sites lateral to Tianshu (ST 25) and Fujie (SP 14), and shallow needling at lateral Shangjuxu (ST 37), treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Number of subjects: 70
Study 24295403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 24295403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21397770 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days
Number of subjects: 202
Study 21397770 — intervention group
Group type: COMPARATOR
Intervention: Vehicle administered twice daily for 3 days
Number of subjects: 202
Study 18454508 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Number of subjects: 382
Study 18454508 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Number of subjects: 382
Study 18454508 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alpha-2a plus ribavirin in genotype 2 patients
Number of subjects: 382
Study 18454508 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alpha-2a plus ribavirin in genotype 2 patients
Number of subjects: 382
Study 18454508 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alpha-2a plus ribavirin in genotype 3 patients
Number of subjects: 382
Study 18454508 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alpha-2a plus ribavirin in genotype 3 patients
Number of subjects: 382
Study 16814647 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 50
Study 16814647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 14508214 — intervention group
Group type: COMPARATOR
Intervention: Predominantly formula fed until term chronological age (PFF-T, n = 119)
Number of subjects: 463
Study 14508214 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominantly human milk fed until term chronological age (PHM-T, n = 43)
Number of subjects: 463
Study 14508214 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 50% energy from human milk before hospital discharge (>= 50% HM, n = 98)
Number of subjects: 463
Study 14508214 — intervention group
Group type: EXPERIMENTAL
Intervention: < 50% of energy from human milk before hospital discharge (< 50% HM, n = 203)
Number of subjects: 463
Study 11006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 60 mg/day orally
Number of subjects: 0
Study 11006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride
Number of subjects: 0
Study 10163482 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet spacer with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Number of subjects: 36
Study 10163482 — intervention group
Group type: COMPARATOR
Intervention: Standard actuator with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Number of subjects: 36
Study 1614687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 426
Study 1614687 — intervention group
Group type: COMPARATOR
Intervention: Anti-DIM medication, vitamins, and combined regimen
Number of subjects: 426
Study 6692967 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral iron therapy (200 mg Fe++ daily)
Number of subjects: 122
Study 6692967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron therapy)
Number of subjects: 122
Study 30926104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with orthodontic treatment
Number of subjects: 84
Study 30926104 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (simulated LLLT with orthodontic treatment)
Number of subjects: 84
Study 30926104 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthodontic treatment only)
Number of subjects: 84
Study 29172851 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 228
Study 29172851 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant radiotherapy)
Number of subjects: 228
Study 26705884 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cadence cycling at 20 RPM
Number of subjects: 17
Study 26705884 — intervention group
Group type: COMPARATOR
Intervention: High cadence cycling at 50 RPM
Number of subjects: 17
Study 24481962 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical antishock trousers (inflated to 70 mmHg) during head-up tilt (HUT)
Number of subjects: 12
Study 24481962 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical antishock trousers (inflated to 70 mmHg) during head-down tilt (HDT)
Number of subjects: 12
Study 24481962 — intervention group
Group type: COMPARATOR
Intervention: Control (no medical antishock trousers) during head-up tilt (HUT)
Number of subjects: 12
Study 24481962 — intervention group
Group type: COMPARATOR
Intervention: Control (no medical antishock trousers) during head-down tilt (HDT)
Number of subjects: 12
Study 22892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 25 mg daily
Number of subjects: 209
Study 22892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 50 mg daily
Number of subjects: 209
Study 22892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 100 mg daily
Number of subjects: 209
Study 22892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 125 mg daily
Number of subjects: 209
Study 22892585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 19858136 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with combined proximal embolic protection and thrombus aspiration
Number of subjects: 206
Study 19858136 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI alone (Control)
Number of subjects: 206
Study 17389702 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol solution treatment (group 1, n = 17)
Number of subjects: 36
Study 17389702 — intervention group
Group type: COMPARATOR
Intervention: No preoperative treatment with Lugol solution (group 2, n = 19)
Number of subjects: 36
Study 15606696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smoked (current or former)
Number of subjects: 299
Study 15606696 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked daily
Number of subjects: 299
Study 15606696 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of smoking
Number of subjects: 299
Study 15606696 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 299
Study 12131078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin meal and follow-through study
Number of subjects: 124
Study 12131078 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 124
Study 10396539 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor/Dietitian group
Number of subjects: 273
Study 10396539 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian group
Number of subjects: 273
Study 10396539 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 273
Study 7572657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 21
Study 7572657 — intervention group
Group type: COMPARATOR
Intervention: Control (no ultrafiltration)
Number of subjects: 21
Study 2269915 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP) ceramic
Number of subjects: 137
Study 2269915 — intervention group
Group type: COMPARATOR
Intervention: Open flap curettage
Number of subjects: 137
Study 2269915 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone implant
Number of subjects: 137
Study 6988947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole and doxycycline
Number of subjects: 42
Study 6988947 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 42
Study 29159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) and hydroxytyrosol (HT) loaded chitosan nanoparticles (CSNPs)
Number of subjects: 10
Study 29159691 — intervention group
Group type: COMPARATOR
Intervention: Vehicle samples (aqueous (AQ) cream)
Number of subjects: 10
Study 30031089 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS intervention (Social problem-solving training program)
Number of subjects: 0
Study 30031089 — intervention group
Group type: COMPARATOR
Intervention: Food for Life (attention-control nutrition intervention)
Number of subjects: 0
Study 26990559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye kernel bread (RKB)
Number of subjects: 0
Study 26990559 — intervention group
Group type: COMPARATOR
Intervention: White wheat flour based bread (WWB)
Number of subjects: 0
Study 23374589 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain-Ag (silver-releasing dressing)
Number of subjects: 181
Study 23374589 — intervention group
Group type: COMPARATOR
Intervention: Biatain (non silver-releasing dressing)
Number of subjects: 181
Study 23374589 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain-Ag (for subgroup with poor healing prognosis)
Number of subjects: 181
Study 23374589 — intervention group
Group type: COMPARATOR
Intervention: Biatain (for subgroup with poor healing prognosis)
Number of subjects: 181
Study 22052102 — intervention group
Group type: COMPARATOR
Intervention: Control (unloaded cycling)
Number of subjects: 7
Study 22052102 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate (6-min moderate intensity)
Number of subjects: 7
Study 22052102 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy (6-min heavy intensity)
Number of subjects: 7
Study 22052102 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 (2-min severe intensity)
Number of subjects: 7
Study 22052102 — intervention group
Group type: EXPERIMENTAL
Intervention: S4 (4-min severe intensity)
Number of subjects: 7
Study 19064973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks for two cycles, followed by cisplatin 40 mg/m(2)/wk concurrent with radiotherapy
Number of subjects: 65
Study 19064973 — intervention group
Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 65
Study 19064973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel-cisplatin followed by CRT
Number of subjects: 65
Study 17115155 — intervention group
Group type: EXPERIMENTAL
Intervention: Shed blood retransfusion (autotransfusion)
Number of subjects: 32
Study 17115155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 32
Study 17115155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (autotransfusion and control)
Number of subjects: 32
Study 17115155 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 14997082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 30 mg x kg(‐1)
Number of subjects: 250
Study 14997082 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid 15 mg x kg(‐1) followed by infusion of 1 mg x kg(‐1) h(‐1)
Number of subjects: 250
Study 12149056 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (12 Gy of 6‐mV photons in 6 fractions)
Number of subjects: 199
Study 12149056 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 199
Study 10405472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant restorations
Number of subjects: 164
Study 10405472 — intervention group
Group type: COMPARATOR
Intervention: Light cured glass-ionomer cement
Number of subjects: 164
Study 10405472 — intervention group
Group type: COMPARATOR
Intervention: Larger composite restorations
Number of subjects: 164
Study 7751258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (mean optimal daily dose: 1,248 mg, mean serum level: 1.12 mEq/L)
Number of subjects: 50
Study 7751258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2346341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 26
Study 2346341 — intervention group
Group type: COMPARATOR
Intervention: Biosynthetic human growth hormone (r-hGH)
Number of subjects: 26
Study 341338 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 7-day treatment
Number of subjects: 150
Study 341338 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 14-day treatment
Number of subjects: 150
Study 341338 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate 14-day treatment
Number of subjects: 150
Study 31612359 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane 3 mL
Number of subjects: 272
Study 31612359 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT) - IV morphine 0.1 mg/kg for severe pain (NRS ≥ 7); IV paracetamol 1 g or IV ketoprofen 100 mg for moderate pain (NRS 4-6)
Number of subjects: 272
Study 28342723 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric overload squat training (six weeks) followed by three consecutive days of running.
Number of subjects: 20
Study 28342723 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT) performing three consecutive days of running without prior eccentric training.
Number of subjects: 20
Study 25537465 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaccades with lower probability
Number of subjects: 0
Study 25537465 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades with varying trial-type probability
Number of subjects: 0
Study 25537465 — intervention group
Group type: EXPERIMENTAL
Intervention: Runs with larger probability of antisaccade trials
Number of subjects: 0
Study 25537465 — intervention group
Group type: EXPERIMENTAL
Intervention: Task switching
Number of subjects: 0
Study 25537465 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior antisaccade trial
Number of subjects: 0
Study 24749263 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group (n = 25) with patient‐controlled epidural analgesia
Number of subjects: 50
Study 24749263 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) with multimodal analgesia (paracetamol, tramadol, ketoprofen)
Number of subjects: 50
Study 24749263 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 20607600 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vegetable intake
Number of subjects: 3080
Study 20607600 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vegetable intake among women taking tamoxifen
Number of subjects: 3080
Study 20607600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake among women taking tamoxifen
Number of subjects: 3080
Study 20607600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake above the median and highest tertile of total vegetable intake among women using tamoxifen
Number of subjects: 3080
Study 19672007 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension-oriented exercise program conducted by a physical therapist
Number of subjects: 71
Study 19672007 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic brochure (Control)
Number of subjects: 71
Study 15927414 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pelvic radiotherapy (RT)
Number of subjects: 714
Study 15927414 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (controls)
Number of subjects: 714
Study 15927414 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pelvic radiotherapy (RT) excluding Grade 1 with superficial myometrial invasion
Number of subjects: 714
Study 15927414 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (controls) excluding Grade 1 with superficial myometrial invasion
Number of subjects: 714
Study 10553846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 9 mg with fentanyl 20 microg
Number of subjects: 76
Study 10553846 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 9 mg with fentanyl 20 microg
Number of subjects: 76
Study 8744464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 1 g every 12 hours for two doses
Number of subjects: 20